Healrna (also known as Huiliao  in Chinese) was officially established in May 2021 within the SUNGENT I-PARK, Suzhou. It is a high-tech company dedicated to providing comprehensive industrialization solutions for nucleic acid drugs.

        The company's business covers many fields including mRNA drug R&D, clinical trial design, and data analysis, and it holds over forty basic technology patents. As a global pioneer in achieving a full industrial chain layout for innovative mRNA animal vaccines, Healrna has established a comprehensive and independent technological barrier spanning from underlying sequence design and efficient delivery systems to large-scale production, setting a new industry benchmark. Its proprietary delivery system technology has exponentially enhanced vaccine efficacy and revolutionized the cost structure of mRNA vaccines for livestock animals, leading the industry trend in cost reduction and efficiency improvement. HealRNA has established a set of pipelines in the field of veterinary (livestock animals, pets) mRNA preventive vaccines and human therapeutic drugs (such as in vivo CAR-T therapies). Recently, a series of groundbreaking advancements has been made in vaccines targeting porcine diarrhea-related viruses and feline infectious peritonitis viruses. Driven by the advanced mRNA technology, Healrna is accelerating the global animal vaccine sector into a new precision medicine era.